Leo Lin, MD, PhD

Assistant Professor (Clinical), University of Utah School of Medicine

Specialties

• Clinical pathology
• Immunology
• Nonmalignant flow cytometry

Education

• Medical Degree—University of California, San Diego School of Medicine
• Doctorate Degree—Biomedical Sciences, University of California, San Diego
• Residency—Clinical Pathology, University of Utah School of Medicine

Certification/Affiliations

• American Board of Pathology

Research Interests

•  Flow cytometry
•  Translational research

Recent Publications

• Potter S, et al. Life threatening platelet transfusion refractoriness due to an anamnestic human leukocyte antigen alloantibody response. Transfusion. 2022
• Lin L, et al. Comparison of next-generation assays for fecal calprotectin vs the PhiCal assay. Am J Clin Pathol. 2022;157(2):252–6.
• Lin L, et al. Experience with false-positive test results on the TaqPath real-time reverse transcription-polymerase chain reaction coronavirus disease 2019 (COVID-19) testing platform. Arch Pathol Lab Med. 2021;145(3):259–61.
• Wyness SP, et al. Clinical and analytical verification of an automated fecal calprotectin immunoassay with extraction device. J Appl Lab Med. 2021;6(4):931–41.
• Lin L, et al. American Society of Clinical Oncology/College of American Pathologists 2018 focused update of breast cancer HER2 FISH testing guidelines results from a national reference laboratory. Am J Clin Pathol. 2019;152(4):479–85.
• Zare SY, et al. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features. Hum Pathol. 2019;83:7–13.
• Zare S, et al. Comparative pathologic analysis of breast cancers classified as HER2/neu-amplified by FISH using a standard HER2/CEP17 dual probe and an alternative chromosome 17 control probe. Am J Surg Pathol. 2018;42(9):1208–15.
• Schooley RT, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection [published correction appears in Antimicrob Agents Chemother. 2018;62(12)].  Antimicrob Agents Chemother. 2017 61(10):e00954–17.